Successful treatment for perinephric abscess with recombinant human granulocyte colony-stimulating factor following nephrectomy in a patient of myelodysplastic syndrome: A case report

Abstract

The 35-year-old man with myelodysplastic syndrome (MDS) and granulocytopenia with dry cough and high fever was eventually found to have a left perinephric abscess of Staphylococcus aureus. He underwent left nephrectomy and drainage of perinephric space in conjunction with appropriate antibiotics. However, because of persistent granulocytopenia, Staph. aureus never cleared up with formation of only poor granulation. Recombinant human granulocyte colony-stimulating factor (G-CSF) was added to the above treatment leading to prompt improvement in granulocytopenia and emergence of the good granulation tissue. G-CSF will probably become one of the important agents in treating MDS with granulocytopenia.

Radical vulvectomy and groin node dissection in a patient with chronic neutropenia—maintenance of leucocyte count using granulocyte colony-stimulating factor

“…As a result of our own experience with GCSF in increasing the neutrophil count in patients receiving cytotoxic chemotherapy it was decided to administer GCSF in this situation. We were further encouraged by reports of colony stimulating factors having been shown to increase neutrophil counts in other benign conditions (5,6).…”

Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)

“…In particular, G-CSF can be administered in patients with MDS to i) increase neutrophils during a severe (life-threatening) infection, ii) to prevent neutropenia-associated infections in those who are known to acquire severe (life threatening) infections (prophylactic use), and iii) as an adjunct to high dose chemotherapy [171,172,[175][176][177][190][191][192][193]. A generally accepted recommendation is to use G-CSF in neutropenic MDS patients who suffer from a severe (life-threatening) infection [172,[175][176][177]194]. Administration of rhGM-CSF may also be effective in these patients [173,174], and can be used in those who fail to respond to G-CSF, have developed anti-G-CSF antibodies, or show severe side effects (e.g.…”

“…Apart from its synergistic effects on erythropoiesis when combined with rhEPO, rhG-CSF is also used in patients with MDS to counteract neutropenia [171,172,[175][176][177][190][191][192][193]. In particular, G-CSF can be administered in patients with MDS to i) increase neutrophils during a severe (life-threatening) infection, ii) to prevent neutropenia-associated infections in those who are known to acquire severe (life threatening) infections (prophylactic use), and iii) as an adjunct to high dose chemotherapy [171,172,[175][176][177][190][191][192][193].…”

“…Cytokines that show beneficial effects in these patients include erythropoietin (EPO) [164][165][166][167][168][169][170], granuloyte colony-stimulating factor (G-CSF) [171,172,[175][176][177], and granulocyte-macrophage colony-stimulating factor (GM-CSF) [173][174][175][176][177].…”

Complicated Upper Urinary Tract Infection

“…A urinary obstruction must be dealt with by either a percutaneous stent, or double J stent, or open intervention. In blood dyscrasias recombinant human granulocyte colony-stimulating factor may be helpful [77]. Unusual causative or accompanying conditions cited before must be cautiously addressed.…”